<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102504</url>
  </required_header>
  <id_info>
    <org_study_id>SOLANUM 2.0.0</org_study_id>
    <nct_id>NCT01102504</nct_id>
  </id_info>
  <brief_title>Supplementation of Lycopene in Carotid Atheroma</brief_title>
  <acronym>SOLANUM</acronym>
  <official_title>Supplementation of Lycopene on Carotid Atheroma: Neovascularisation and Morphology (SOLANUM) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is the second leading cause of death worldwide. One of the causes of stroke which can
      be treated is narrowing of the carotid artery. Currently the only definite treatment option
      is surgery or endovascular treatment. All patients not qualified for or awaiting surgery are,
      therefore, left with best medical therapy and with a yearly risk of stroke anywhere between
      1% - 35% depending on the severity of the disease.

      The study will use the properties of a tomato extract containing lycopene. Previously studies
      have demonstrated beneficial properties of tomato extracts:

        1. It decreases lipid oxidation

        2. It decreases DNA damage

        3. It has properties that reduce the speed and amount of cell divisions that inflammatory
           and smooth muscle cells undergo (both of these cell types contribute to atheroma
           formation).

      The investigators wish to assess whether long-term food supplementation with a tomato extract
      containing lycopene could influence atherosclerotic plaque characteristics. The investigators
      will assess this using Magnetic Resonance Imaging of the plaque and transcranial Doppler
      ultrasonography for counting the number of blood clots that go to the brain's arteries.
      Furthermore the investigators wish to examine the effect of long-term food supplementation
      with a tomato extract containing lycopene on blood cholesterol levels and lipid oxidation and
      blood markers of inflammation and injury of the inner lining of the arteries.

      This will be a single center, double blind, randomised, placebo controlled study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plaque morphology and biomechanics on magnetic resonance</measure>
    <time_frame>12 months</time_frame>
    <description>Magnetic resonance imiging (MRI) of the plaques will be performed with detailed assessment of plaque morphological parameters: fibrous cap, lipid rich necrotic core, intraplaque hemorrhage. Sheer stress and wall stress will be calculated using magnetic resonance data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum levels of lycopene - a component of the tomato extract</measure>
    <time_frame>12 months</time_frame>
    <description>Serum levels of lycopene obtained through long-time supplementation with a tomato extract containing lycopene.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microemboli on transcranial Doppler (TCD)</measure>
    <time_frame>12 months</time_frame>
    <description>Amount of microeboli detected using bilateral middle cerebral artery (MCA) TCD monitoring (DWL, Germany, 2-MHz probe). TCD will be performed by a single investigator (KPB) for 1 hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemistry</measure>
    <time_frame>12 months</time_frame>
    <description>Serum levels of total cholesterol, low-denisty lipoproteins (LDL), oxidized-LDL (oxy-LDL), high-density lipoproteins (HDL), C-reactive protein (CRP) as biomarkers of atherosclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of blood circulating endothelial cells and endothelial progenitor cells</measure>
    <time_frame>12 months</time_frame>
    <description>Levels of blood circulating endothelial cells and endothelial progenitor cells will be measured as markers for endothelial injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque neovascularisation</measure>
    <time_frame>12 months</time_frame>
    <description>Plaque enhancement on dynamic contrast-enhanced MRI perfusion imaging using gadolinium-based contrast agent as a surrogate marker for plaque inflammation and neovascularisation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Carotid Atherosclerotic Disease</condition>
  <arm_group>
    <arm_group_label>Tomato extract (Ateronon)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ateronon</intervention_name>
    <description>Tomato extract containing 28 mg lycopene/ day</description>
    <arm_group_label>Tomato extract (Ateronon)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 - 90 years old,

          -  Clinically documented carotid symptomatic atherosclerotic disease (symptomatic disease
             will be considered if one of the following has occurred within 2 months prior to
             symptoms:

               1. Amaurosis fugax

               2. Transient ischemic attack (TIA)

               3. Stroke (ipsilaterally to the stenotic artery)

          -  &gt;30% stenosis on initial B-mode ultrasonography imaging,

          -  Written, informed consent.

        Exclusion Criteria:

          -  Age &lt;40 years old or &gt;90 years old,

          -  Time from symptom to recruitment &gt; 2 months

          -  &lt;30% stenosis on B-mode ultrasonography imaging,

          -  Scheduled for surgical/endovascular intervention within 3 months,

          -  High-dose statin therapy (&gt;80 mg/day fluvastatin; &gt;40 mg/day simvastatin; &gt;40 mg/day
             pravastatin; &gt;10 mg/day atorvastatin; &gt;10 mg/day rosuvastatin 21),

          -  Other lipid-lowering therapy (fibric acid derivatives, niacin â‰¥250 mg/day, resins,
             ezetimibe, fish-oil supplements),

          -  Chronic use of high dose aspirin &gt;325 mg/day,

          -  Allergy or hypersensitivity to tomatoes and tomato products, gadolinium and history of
             any other significant atopy/allergy (e.g. soy, whey, lutein, lecithin),

          -  Contraindications for MRI studies including claustrophobia, any MRI non-compatible
             devices implanted (vascular clips, metal sutures, craniofix, cardiac pacers,
             endovascular stents/coils, etc.),

          -  Known renal impairment with creatinine clearance &lt;50 ml/min (as per departmental
             policy),

          -  Women of childbearing potential,

          -  Inability to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan H Gillard, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Department of Radiology, University of Cambridge, Addenbrooke's Hospital, Hills Road, CB2 0QQ Cambridge, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002 Dec 3;106(23):2884-7.</citation>
    <PMID>12460866</PMID>
  </reference>
  <reference>
    <citation>Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G, Badimon JJ. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005 Jul 5;46(1):106-12.</citation>
    <PMID>15992643</PMID>
  </reference>
  <reference>
    <citation>Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, Warburton EA, Hayes PD, Varty K, Boyle JR, Gaunt ME, Zalewski A, Gillard JH. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009 Jun 2;53(22):2039-50. doi: 10.1016/j.jacc.2009.03.018.</citation>
    <PMID>19477353</PMID>
  </reference>
  <reference>
    <citation>Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, Chu B, Takaya N, Liu F, Polissar NL, Neradilek B, Raichlen JS, Cain VA, Waterton JC, Hamar W, Hatsukami TS. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008 Mar;155(3):584.e1-8. doi: 10.1016/j.ahj.2007.11.018. Epub 2008 Jan 18. Erratum in: Am Heart J. 2008 Jun;155(6):1127.</citation>
    <PMID>18294500</PMID>
  </reference>
  <reference>
    <citation>Carpenter KL, Hardwick SJ, Albarani V, Mitchinson MJ. Carotenoids inhibit DNA synthesis in human aortic smooth muscle cells. FEBS Lett. 1999 Mar 19;447(1):17-20.</citation>
    <PMID>10218573</PMID>
  </reference>
  <reference>
    <citation>Das S, Otani H, Maulik N, Das DK. Lycopene, tomatoes, and coronary heart disease. Free Radic Res. 2005 Apr;39(4):449-55.</citation>
    <PMID>16032783</PMID>
  </reference>
  <reference>
    <citation>Holvoet P, Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis. 1998 Apr;137 Suppl:S33-8. Review.</citation>
    <PMID>9694539</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Karol Palwel Budohoski</investigator_full_name>
    <investigator_title>Resident in Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>carotid atheroma</keyword>
  <keyword>plaque vulnerability</keyword>
  <keyword>stroke risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

